Lung cancer risk prediction: Prostate, lung, colorectal and ovarian cancer screening trial models and validation

Journal of the National Cancer Institute

Volumn 103, Issue 13, 2011, Pages 1058-1068

  Tammemagi, C Martin ^a   Pinsky, Paul F ^b   Caporaso, Neil E ^b   Kvale, Paul A ^c   Hocking, William G ^d   Church, Timothy R ^e   Riley, Thomas L ^f   Commins, John ^f   Oken, Martin M ^g   Berg, Christine D ^b   Prorok, Philip C ^b  

^a BROCK UNIVERSITY   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d MARSHFIELD CLINIC   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

^g North Memorial Humphrey Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CALIBRATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MODEL; OVARY CANCER; PRIORITY JOURNAL; PROBABILITY; QUESTIONNAIRE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; SOCIAL STATUS; THORAX RADIOGRAPHY; VALIDATION STUDY;

ADULT; AGED; AREA UNDER CURVE; CANADA; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); EARLY DETECTION OF CANCER; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SMOKING; SMOKING CESSATION;

EID: 79955842511     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr173     Document Type: Article

References (65)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2010. Toronto, Canada: Canadian Cancer Society; 2010.
2. Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. (Pubitemid 40372904)
4. Aberle DR, Berg CD, Black WC, et al. The national lung screening trial: overview and study design. Radiology. 2011;258(1):243-253.
5. National Cancer Institute (U.S.). Lung cancer trial results show mortality benefit with low-dose CT. http://www.cancer.gov/newscenter/ pressreleases/NLSTresultsRelease.
6. Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health. 1978;32(4):303-313. (Pubitemid 9067838)
7. Prindiville SA, Byers T, Hirsch FR, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev. 2003;12(10):987-993. (Pubitemid 37310253)
8. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470-478. (Pubitemid 36432421)
9. Cassidy A, Myles JP, Liloglou T, et al. Defining high-risk individuals in a population-based molecular-epidemiological study of lung cancer. Int J Oncol. 2006;28(5):1295-1301.
10. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99(9):715-726. (Pubitemid 47073532)
11. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98(2):270-276. (Pubitemid 351161249)
12. Spitz MR, Etzel CJ, Dong Q, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila Pa). 2008;1(4):250-254.
13. Etzel CJ, Kachroo S, Liu M, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res (Phila Pa). 2008;1(4):255-265.
14. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. . (2nd edition). Chest. 2007;132(3) (suppl):29S-55S. (Pubitemid 47502798)
15. Tammemagi MC, Freedman MT, Pinsky PF, et al. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study. J Thorac Oncol. 2009;4(6):710-721.
16. Nomura A, Heilbrun LK, Stemmermann GN. Body mass index as a predictor of cancer in men. J Natl Cancer Inst. 1985;74(2):319-323. (Pubitemid 15112118)
17. Hoffmans MD, Kromhout D, Coulander CD. Body Mass Index at the age of 18 and its effects on 32-year-mortality from coronary heart disease and cancer. A nested case-control study among the entire 1932 Dutch male birth cohort. J Clin Epidemiol. 1989;42(6):513-520.
18. Knekt P, Heliovaara M, Rissanen A, et al. Leanness and lung-cancer risk. Int J Cancer. 1991;49(2):208-213.
19. Kark JD, Yaari S, Rasooly I, et al. Are lean smokers at increased risk of lung cancer? The Israel Civil Servant Cancer Study. Arch Intern Med. 1995;155(22):2409-2416.
20. Singh PN, Lindsted KD. Body mass and 26-year risk of mortality from specific diseases among women who never smoked. Epidemiology. 1998;9(3):246-254. (Pubitemid 28194232)
21. Olson JE, Yang P, Schmitz K, et al. Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. Am J Epidemiol. 2002;156(7):606-615.
22. Kabat GC, Miller AB, Rohan TE. Body mass index and lung cancer risk in women. Epidemiology. 2007;18(5):607-612. (Pubitemid 47263036)
23. Kondo T, Hori Y, Yatsuya H, et al. Lung cancer mortality and body mass index in a Japanese cohort: findings from the Japan Collaborative Cohort Study (JACC Study). Cancer Causes Control. 2007;18(2):229-234. (Pubitemid 46215319)
24. Kabat GC, Kim M, Hunt JR, et al. Body mass index and waist circumference in relation to lung cancer risk in the women's health initiative. Am J Epidemiol. 2008.
25. Kollarova H, Machova L, Horakova D, et al. Is obesity a preventive factor for lung cancer? Neoplasma. 2008;55(1):71-73.
26. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002;16(2):217-226. 229; discussion 230-232.
27. Schwartsburd PM. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev. 2003;22(1):95-102. (Pubitemid 36363518)
28. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol. 2006;16(1):80-88. (Pubitemid 43139712)
29. Malkinson AM, Bauer A, Meyer A, et al. Experimental evidence from an animal model of adenocarcinoma that chronic inflammation enhances lung cancer risk. Chest. 2000;117(5) (suppl 1):228S. (Pubitemid 30326961)
30. Blanco D, Vicent S, Fraga MF, et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia. 2007;9(10):840-852. (Pubitemid 47623424)
31. Walser T, Cui X, Yanagawa J, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5(8):811-815.
32. Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med. 2009;15(4):303-307.
33. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6) ((suppl):273S-309S.
34. Gohagan JK, Prorok PC, Hayes RB, et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6) (suppl):251S-272S.
35. Oken MM, Marcus PM, Hu P, et al. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst. 2005;97(24):1832-1839. (Pubitemid 43039889)
36. Parkin DM, Moss SM. Lung cancer screening: improved survival but no reduction in deaths - the role of "overdiagnosis". Cancer. 2000;89(11) (suppl):2369-2376.
37. Marcus PM, Bergstralh EJ, Zweig MH, et al. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst. 2006;98(11):748-756. (Pubitemid 43983298)
38. Schwartz AG, Swanson GM. Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan. Cancer. 1997;79(1):45-52. (Pubitemid 26425506)
39. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354(4):333-342. (Pubitemid 43145058)
40. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
41. Harrell FE. Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001.
42. Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York, NY: Springer; 2009.
43. Hosmer DW Jr., Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley&Sons, Inc; 1999.
44. Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. Biostatistics. 2005;6(2):227-239. (Pubitemid 41240355)
45. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
46. Cronin KA, Gail MH, Zou Z, et al. Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst. 2006;98(9):637-640. (Pubitemid 43904847)
47. Whittemore AS. Evaluating health risk models. Stat Med. 2010;29(23):2438-2452.
48. Godschalk RW, Feldker DE, Borm PJ, et al. Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidemiol Biomarkers Prev. 2002;11(8):790-793. (Pubitemid 34851917)
49. Mizoue T, Kasai H, Kubo T, et al. Leanness, smoking, and enhanced oxidative DNA damage. Cancer Epidemiol Biomarkers Prev. 2006;15(3):582-585.
50. Mizoue T, Tokunaga S, Kasai H, et al. Body mass index and oxidative DNA damage: a longitudinal study. Cancer Sci. 2007;98(8):1254-1258. (Pubitemid 46993546)
51. Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007;165(8):874-881. (Pubitemid 46536660)
52. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882-890. (Pubitemid 38657490)
53. Altman DG, Lausen B, Sauerbrei W, et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86(11):829-835. (Pubitemid 2100935)
54. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633-637. (Pubitemid 351483367)
55. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40(5):616-622. (Pubitemid 351601203)
56. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638-642. (Pubitemid 351483366)
57. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40(12):1404-1406.
58. Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008;40(12):1407-1409.
59. Rafnar T, Sulem P, Stacey SN, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet. 2009;41(2):221-227.
60. Landi MT, Chatterjee N, Yu K, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85(5):679-691.
61. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010;28(16):2719-2726.
62. Yee J, Sadar MD, Sin DD, et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 2009;27(17):2787-2792.
63. Chaturvedi AK, Gaydos CA, Agreda P, et al. Chlamydia pneumoniae infection and risk for lung cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1498-1505.
64. Church TR, Anderson KE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev. 2009;18(1):260-266.
65. Tammemagi MC, Lam SC, McWilliams AM, et al. Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. Cancer prevention research 2011;4(4):552-61.